RecruitingNCT03146676
The Ohio State University Dermatology Biorepository
Sponsor
Ohio State University
Enrollment
175 participants
Start Date
Apr 19, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
Eligibility
Inclusion Criteria3
- Seen by an Ohio State University (OSU) Dermatology provider on the main University Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this protocol
- Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals
- Willingness to participate in a research study.
Exclusion Criteria1
- Inability to provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03146676
Related Trials
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
NCT0688819312 locations
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
NCT041155661 location
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT0722839054 locations
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT0722556943 locations
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225101 locations